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Abstract  13 
Medication and doping control has been established in horseracing to ensure the integrity of 14 
the sport and the welfare of the horses. This ensures that horses do not compete under the 15 
influence of any drugs, including omeprazole, a therapeutic medication used to treat equine 16 
gastric ulcer syndrome. In this study, pharmacokinetic data were produced in equine plasma 17 
and urine following an oral administration of 4 mg/kg of generic buffered formulation of 18 
omeprazole to six Thoroughbred horses in five daily doses to determine an appropriate 19 
screening limit and detection time in equine plasma and to assess whether the current detection 20 
time of 72 hours in equine urine would be applicable when an alternative omeprazole product 21 
is administered. Cmax of 436 – 2432 ng/mL and AUC0-tau of 1476 – 4371 ng.hr/mL were 22 
obtained for plasma and indicated, in conjunction with other published oral omeprazole studies, 23 
that an appropriate plasma screening limit would be 500 pg/mL with a detection time of 48 24 
hours. Urine analysis showed that omeprazole could be detected for up to 25 hours above the 25 
previously established urine screening limit of 500 pg/mL, and thus, indicated that the detection 26 
time advice could be potentially reduced from 72 hours to 48 hours to allow more 27 
comprehensive treatment of gastric  lesions.   28 
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Introduction  31 
Equine Gastric Ulcer Syndrome (EGUS) refers to a spectrum of diseases, including 32 
hyperkeratotic, erosive and ulcerative lesions of the squamous mucosa and hyperaemic, erosive 33 
and ulcerative disease of the glandular mucosa, and affects many breeds of horse, including 34 
Thoroughbred racehorses. EGUS is now differentiated into Equine Squamous Gastric Disease 35 
(ESGD) and Equine Glandular Gastric Disease (EGGD) according to the region of the stomach 36 
affected (Sykes, 2015a). The highest prevalence of ESGD occurs in Thoroughbred racehorses 37 
with 37% of untrained horses affected, increasing to 80–100% within 2–3 months of race 38 
training (Murray, 1996; Begg, 2003; Vatistas, 1999). EGGD is less well understood with 39 
reported prevalences of between 47% (Begg, 2003) and 65% (Sykes, 2015b) in Thoroughbred 40 
racehorses in Australia.  Omeprazole is a proton pump inhibitor and its oral dosage is currently 41 
considered the treatment of choice for ESGD and EGGD.  42 
Provision of high quality, evidence based information as to when to withdraw omeprazole and 43 
other medications in horses in training prior to a race day is a priority for horseracing regulators. 44 
A tenet of medication control in horseracing is that horses do not race under the 45 
pharmacological effects of drugs but are able to be treated with medication in training in the 46 
interests of their health and welfare. Medication control involves screening blood or urine 47 
samples to detect parent drug or metabolites and is not usually an issue of drug detection, but 48 
about determining the concentration at which a drug no longer has a significant 49 
pharmacological effect in a population of horses.  With omeprazole, this is complicated by the 50 
range of doses used, oral formulation, high inter-individual variability (>30%) and by the 51 
mechanism of action of the drug.   52 
Omeprazole is a prohibited substance according to the rules of the majority of racing 53 
jurisdictions with a wish to facilitate its use close to racing so that there is no recurrence of 54 
EGUS in susceptible horses whilst still not permitting racing under its direct effects.  The 55 
European Horserace Scientific Liaison Committee (EHSLC) is a technical group representing 56 
European racing regulatory authorities who develop medication control advice in a harmonised 57 
way, based on Detection Times (DTs) and associated Screening Limits (SLs). The DT is an 58 
observed time point when the plasma or urine concentration falls below the respective SL 59 
following the last therapeutic dose. A DT of 72 hours was recommended by the EHSLC in 60 
2006 for the control of omeprazole, based on a multiple administration study of GastroGard® 61 
paste (37 % w/w) at a daily dose of 4 mg/kg for 28 days (Hannan, 2008). 62 
In the last two years there has been a flurry of publications regarding the horse plasma PK of 63 
different omeprazole oral formulations.  Given the large variability so reported for the plasma 64 
PK of the same formulation of omeprazole (GastroGard®) coupled with newer formulations 65 
of omeprazole licensed for use in the horse, the aim of this study was to assess the suitability 66 
of the current urine DT of 72 hours for omeprazole, its associated urine International Screening 67 
Limit (ISL) and to use the plasma data generated to propose an associated ISL for omeprazole 68 
in equine plasma.  69 
 70 
Materials and Methods 71 
Chemicals and reagents 72 
Ammonium acetate was obtained from Sigma-Aldrich (UK) and methanol, ethyl acetate, 73 
sodium hydroxide, glacial acetic acid and hexane were from Fisher Scientific Ltd (UK). Water 74 
was purified using a Triple Red Duo Water system (Triple Red Laboratory Technology, UK).  75 
Omeprazole was purchased as 1 mg/mL solution in methanol from Cerilliant and omeprazole-76 
(5-methoxy-d3) as powder from Sigma-Aldrich. A stock solution at a concentration of 1 mg/mL 77 
was prepared in methanol for omeprazole-d3, and stored at – 20 °C. Stock solutions were 78 
subsequently diluted with methanol in order to obtain separate spiking solutions at appropriate 79 
concentrations.  80 
 81 
 82 
Administration study 83 
Six Thoroughbred horses (1 filly and 5 geldings) with a mean ± SD weight of 523.2 ± 26.1 kg, 84 
aged from 4 to 9 years old, exercised in a manner consistent with that used in British training 85 
yards, fed a normal racehorse diet and housed at the British Horseracing Authority’s Centre for 86 
Racehorse Studies (Newmarket, UK) were used for this study.  The study was ethically 87 
approved with the horses and personnel involved licensed under the UK’s Animals (Scientific 88 
Procedures) Act.  A control blood and urine sample was taken from each horse on each of two 89 
days preceding dosing and again immediately before the first dose, via an intravenous catheter 90 
(Milacath®) placed into the left jugular vein of each horse on that first day of dosing.  A dose 91 
of 4 mg/kg of UlcerGold® paste (37 % w/w, Zoetis) was administered orally in five daily doses 92 
at 9 am after a cereal-based racehorse mix had been given at 6 am. Hay was available ad lib. 93 
All the urine samples voided were collected following the first dose for 24 hours, immediately 94 
before each subsequent dose and following the final dose for up to 263 hours (12 days). Blood 95 
samples were collected immediately before each dose was administered and at 0.5, 1, 1.5, 2, 3, 96 
4, 5, 6, 7, 9, 11, 13 and 15 hours following the first and the final dose, as well as, 23, 31, 47, 97 
71, 95, 119, 143, 167, 215 and 263 hours following the final dose. Blood samples were 98 
collected in lithium heparin tubes and were centrifuged to separate plasma immediately after 99 
collection. Urine and plasma samples were stored at -20 ºC prior to analysis.  100 
Sample analysis 101 
Plasma and urine samples were extracted and analysed using quantitative liquid 102 
chromatography tandem mass spectrometry (LC-MS/MS) methods which had been validated 103 
for omeprazole using measures of linearity, intra- and inter-batch precision and accuracy, 104 
specificity, selectivity and sensitivity (adhering to internal EHSLC quantitative method 105 
validation guidelines).  106 
Plasma and urine detection methods were quantitatively validated in the ranges of 0.025 – 20 107 
ng/mL and 0.1 – 20 ng/mL, respectively, and were shown to be linear with correlation 108 
coefficients greater than 0.99 when a weighting factor of 1/x was used. The methods for plasma 109 
and urine analysis were shown to be accurate and reproducible with low inter-batch variability 110 
for precision (within ± 7.0% for plasma and ± 6.2% for urine) and accuracy (within ± 3.6% for 111 
both plasma and urine) at all QC concentrations (0.025, 0.075, 10 and 17 ng/mL in plasma and 112 
0.1, 0.25, 10 and 17 ng/mL in urine).  QC samples diluted 1-in-100 also produced acceptable 113 
results (within ± 4.9% in plasma and ± 13.0% in urine). 114 
During plasma extraction, each batch included a calibration line in duplicate at concentrations 115 
of 0.025, 0.05, 0.1, 0.5, 1, 5, 10 and 20 ng/mL and QC samples in duplicate at concentrations 116 
of 0.075, 10 and 17 ng/mL. 1 mL aliquots of plasma were spiked at a concentration of 100 117 
ng/mL of omeprazole-d3. Plasma proteins were precipitated by addition of 0.5 mL of 118 
acetonitrile and the sample was subsequently diluted with 7 mL of aqueous phosphate buffer 119 
(1 M, pH 6.8) and centrifuged at 3000 rpm for 15 minutes. Solid phase extraction (SPE) was 120 
performed using Varian Nexus (60 mg, 3 mL) cartridges, which were conditioned with 2 mL 121 
of methanol followed by 2 mL of water prior to sample loading. Cartridges were washed with 122 
1 mL of water prior to eluting with 1 mL of methanol: acetonitrile (60:40, v:v).  123 
During urine extraction, each batch included a calibration line in duplicate at concentrations of 124 
0.1, 0.25, 0.5, 1, 2, 5, 10 and 20 ng/mL and QC samples in duplicate at concentrations of 0.25, 125 
10 and 17 ng/mL. 1 mL aliquots of urine were spiked at a concentration of 100 ng/mL of 126 
omeprazole-d3. Samples were diluted with 1 mL of aqueous ammonium acetate buffer (0.1 M, 127 
pH 9.0). SPE was performed using Varian Nexus (60 mg, 3 mL) cartridges, which were 128 
conditioned with 2 mL of methanol followed by 2 ml of water prior to sample loading. 129 
Cartridges were washed with 2 mL of hexane prior to eluting with 2 mL of methanol: ethyl 130 
acetate (10:90, v:v). Liquid-liquid extraction (LLE) was performed by adding 1.5 mL of 131 
purified water.  132 
Following the extraction, both urine and plasma extracts were dried at ambient temperature 133 
under oxygen-free nitrogen and subsequently reconstituted in 100 µL of methanol and 100 µL 134 
of aqueous ammonium acetate buffer (10 mM, pH 6.8). Extracts were transferred into glass LC 135 
vials and 5 µL was injected into the LC-MS/MS system. 136 
Sample analysis was performed on a LC-MS/MS system consisting of a Waters Acquity I-137 
Class UPLC interfaced with a Waters Xevo TQ-S triple quadrupole mass spectrometer 138 
operating in positive electrospray ionisation mode at a capillary voltage of 2.0 kV, a source 139 
temperature of 150 °C and a desolvation gas temperature at 550 °C. Collision gas was argon at 140 
a flow rate of 0.15 mL/min. Selected reaction monitoring (SRM) was performed for 141 
omeprazole using the precursor ion of m/z 346.0 and the product ions of m/z 198.1 (for 142 
quantification), m/z 151.0 and m/z 136.1 (for qualification) at cone voltage of 8 V and collision 143 
energy of 10, 30 and 32 eV, respectively. The SRM transition of m/z 349.0 to m/z 198.1 was 144 
used for omeprazole-d3 (cone voltage of 8 V and collision energy of 10 eV).  145 
Chromatographic separation was achieved on an Acquity HSS T3 (100 mm x 2.1 mm, 1.8 µm) 146 
reversed phase UPLC column using ammonium acetate in methanol (10 mM, pH 6.8) and 147 
aqueous ammonium acetate (10 mM, pH 6.8) as mobile phases. A gradient was operated at 60 148 
ºC and at a flow rate of 0.4 mL/min. It was started at 20 % organic for 0.5 minutes followed by 149 
an increase to 99.9 % organic at 5.5 minutes. This was held for 1 minute before resuming the 150 
initial conditions and re-equilibrating for 1.5 minutes. The total run time was 8.5 minutes.  151 
 152 
 153 
Pharmacokinetic evaluation  154 
Pharmacokinetic parameters were estimated using non-compartmental analysis with Phoenix 155 
WinNonlin 6.0 (Pharsight Corporation, Cary, NC). The area under the plasma curve for the 156 
first 24 hours post final dose (AUC0-tau) was calculated using the log-linear trapezoidal rule. 157 
The estimated average concentration at steady-state (Cavg) was determined from the AUC0-tau 158 
divided by the dosing interval of 24 hours.  159 
The methodology outlined by Toutain and Lassourd 2002 was used to estimate the effective 160 
plasma concentration (EPC), irrelevant plasma concentration (IPC), irrelevant urine 161 
concentration (IUC) and DT. The EPC was determined from the average steady-state plasma 162 
concentration (Cavg,ss) and estimated by dividing the AUC0-24 for the last dose by the dosing 163 
interval (24 hours). The IPC creates the basis for the plasma SL, which is the concentration 164 
where the drug is no longer pharmacologically significant. The IPC was calculated by dividing 165 
the EPC by a safety factor of 500, to ensure there is no significant pharmacological effect for 166 
the majority of horses in a population. 167 
 168 
Results 169 
Pharmacokinetic analysis for orally administered omeprazole in plasma 170 
Omeprazole was detected in the post-administration plasma samples from all six horses (Figure 171 
1). Maximum concentrations (Cmax) were measured between 436 and 3304 ng/mL between 0.5 172 
and 4 hours (tmax) following either the first or final dose (Table 1). There was very little 173 
accumulation of omeprazole in plasma as shown by the trough levels, from the first dose 174 
through to dose four.  175 
The terminal half-life (t1/2) ranges from 6 to 18 hours and the AUC0-tau ranges from 1476 to 176 
4371 ng.hr/mL. The estimated mean and standard deviation for Cavg,ss omeprazole 177 
concentration was 120 ± 46 ng/mL, which can be considered as the effective plasma 178 
concentration (EPC) for the 4 mg/kg once a day oral regimen in Thoroughbred horses. Different 179 
safety factors were applied to the EPC value to establish the appropriate irrelevant plasma 180 
concentration (IPC) (Table 2).  Using a safety factor of 500 the estimated IPC is 240 pg/mL 181 
with a corresponding DT of 47 hours.  182 
Pharmacokinetic analysis for orally administered omeprazole in urine 183 
Omeprazole was detected in the post-administration samples from all six horses (Figure 2). 184 
The Cmax of omeprazole varied between 55 and 504 ng/mL and were observed between 2 and 185 
11 hours either following the first or final dose administered (Table 3). The ISL of 500 pg/ml 186 
for omeprazole in urine was exceeded for up to 25 hours following the final dose, whilst 187 
detection was still possible at significantly lower concentrations for up to 71 hours post-188 
administration.  189 
 190 
Discussion 191 
Omeprazole is a therapeutic drug which attracts debate with regards to its use in horseracing. 192 
In two studies which investigated omeprazole’s effect on performance markers in healthy 193 
horses, no statistically significant improvement (Kollias-Baker, 2001; McKeever, 2006). 194 
However, it has been shown to improve racing performance in the sense of returning a horse 195 
to a normal condition (Johnson, 2001). It therefore remains a therapeutic but prohibited 196 
substance on raceday and is controlled via an ISL in urine with related DT advice in most 197 
racing jurisdictions.  198 
This study set out to provide data to re-evaluate existing international regulatory omeprazole 199 
DT advice, the existing ISL in urine and to support a new ISL in plasma. An IPC can be used 200 
as the basis to propose a new plasma SL. For the purposes of determining an IPC for an oral 201 
therapy, Toutain and Lassourd 2002 recommend using pharmacokinetic data from an 202 
intravenous study at the therapeutic oral dose. The only published intravenous studies for 203 
omeprazole in horse with resulting pharmacokinetic parameters are those by Sykes et al. 2015d 204 
and Jenkins et al. 1992. Both intravenous administration studies were at 0.5 mg/kg, and not the 205 
4 mg/kg used orally in this case, and the clearance values determined for a single dose were 206 
12.9 (Sykes et al. 2015d) and 14.7 (Jenkins et al. 1992) mL/min/kg. The estimated IPC from 207 
these intravenous studies are 430 (Sykes et al. 2015d) and 379 (Jenkins et al. 1992) pg/mL 208 
using a safety factor of 500 for a dose of 4 mg/kg. These values are higher but similar to the 209 
IPC determined from the oral pharmacokinetics determined in the herein study (240 pg/mL).    210 
Recent oral pharmacokinetic studies involving omeprazole carried out for the purposes of 211 
bioequivalence investigation have not had sufficient analytical sensitivity for the purposes of 212 
DT advice. They have shown that the PK of omeprazole in plasma is not significantly altered 213 
following the administration of different formulations (enteric coated granules versus buffering 214 
with an alkaline medium) when compared with GastroGard® (buffered) (Birkmann et al. 2014; 215 
Sykes et al. 2015c). Computed area under the curve (AUC0-∞) for the Sykes et al. 2015c study 216 
was shown to be approximately 417 – 2083 ng.hr/mL following a single 4 mg/kg dose of 217 
GastroGard® to 12 Thoroughbred horses. In another PK study following oral multi-dose 218 
administration of 4 mg/kg per day of a new gastro-resistant omeprazole formulation to horses 219 
the AUC0-∞ was 1382±861 ng.hr/mL on day 1 slightly reducing to 831±387 ng.hr/mL on day 220 
29 (DiSalvo et al. 2016). One study that was carried out for the purposes of determining a DT 221 
in horseracing showed no significant change in AUC0-tau despite four daily oral doses of 3.7 – 222 
5.2 mg/kg of GastroGard® to nine Thoroughbred horses (Knych, 2017). These 223 
pharmacokinetic parameters obtained by Knych et al. included an average AUC0-tau of 305 ± 224 
141 ng.hr/mL and an average steady-state serum concentration (Cavg) of 12.7 ± 5.89 ng/mL 225 
which are considerably different to those obtained by the other studies. 226 
Although direct extrapolations between formulation across studies is not possible due to high 227 
inter-individual variability between animals, the small number of horses used in different 228 
studies and different analytical methods, any indirect extrapolations should be made with 229 
caution, the plasma exposure, as determined by both Cmax and AUC, in this herein oral 230 
UlcerGold® administration at 4 mg/kg per day is consistent with the Birkmann et al. 2014; 231 
Sykes et al. 2015c and DiSalvo et al. 2016 studies which were also carried out at the same 232 
dose. However, a much higher plasma exposure (~10 times) was observed in these studies 233 
compared with the omeprazole serum exposure by Knych et al. 2017 at the same dose.  234 
Since SLs are calculated from drug exposure measurements at the therapeutic dose, the 235 
discrepancy between the study by Knych et al. 2017 and the other studies may make it difficult 236 
to harmonise SLs across racing jurisdictions. The only major difference between the Knych et 237 
al. 2017 study and the other studies is that serum concentrations were analysed for the former 238 
and plasma for the latter. The study by Knych et al. 2017 used serum separator tubes; one 239 
explanation for the apparent lower exposure may be that omeprazole diffused into the 240 
separating gel, causing a reduction in the measured serum drug concentration. Alternatively, 241 
serum concentration for omeprazole may be lower than the corresponding plasma 242 
concentration due to lower omeprazole binding to serum as part of the clotting process. 243 
Omeprazole is known to have high plasma protein binding, however, a lower binding affinity 244 
to serum proteins will lead to a lower omeprazole serum concentration. In this case a lower SL 245 
would be required for serum; however, further examination of the serum data suggests that the 246 
DT will be similar to the plasma studies based upon an irrelevant serum concentration. 247 
One way forward with regard to generating an ISL in plasma for the oral administration of 248 
omeprazole is to use the IPC calculated from the published intravenous studies. In fact, Toutain 249 
and Lassourd 2002 recommend using intravenous data for the determination of the IPC, 250 
however, for omeprazole the intravenous studies are at a dose eight times smaller than that for 251 
the herein oral study. Assuming dose linear pharmacokinetics between 0.5-4 mg/kg then the 252 
IPC determined from the intravenous studies would encompass all oral formulations of 253 
omeprazole as it would represent the maximum exposure resulting from an oral administration 254 
(i.e. bioavailability = 100%). 255 
Plasma data from the herein UlcerGold® study shows that omeprazole can be detected for up 256 
to 287 hours post-administration above the LLOQ of the 25 pg/mL of the method following an 257 
oral administration of 4 mg/kg per day. However, the DT of 47 hours was determined using an 258 
IPC of 240 pg/mL. Previously, omeprazole has been detected in plasma for up to 24 hours post-259 
administration when 4 mg/kg of GastroGard® (37 % w/w) was orally administered for 28 days 260 
(Hannan, 2008) . This shorter detection time was due to lower method sensitivity (LLOQ of 1 261 
ng/mL). The results from these two studies are consistent as omeprazole was detected for up 262 
to 23 hours post-administration above the concentration of 1 ng/mL in the herein study. 263 
A DT of 47 hours in plasma using an IPC of 240 pg/mL and 25 hours in urine using the ISL of 264 
500 pg/mL was calculated for omeprazole based on six horses in this study. However, if a 265 
plasma screening limit of 500 pg/mL was applied, based upon the IPC determined from 266 
intravenous clearance, then the DT would be 31 hours. Interestingly, an IUC of 500 pg/mL can 267 
be estimated from this study by multiplying a plasma SL of 500 pg/mL by the urine to plasma 268 
steady-state omeprazole concentration ratio (Rss=1) which is in fact equal to (and therefore 269 
supports) the current urine ISL of 500 pg/mL for omeprazole.   270 
Tellez et al. 2005 have shown that a single oral 4 mg/kg dose of omeprazole (GastroGard®) 271 
increases stomach contents pH above a control group for up to 24 hours. Furthermore, Merritt 272 
et al. 2003 have shown that 4 mg/kg per day oral dose GastroGard® for 7 days statistically 273 
increases intragastric pH for up to 14 hours relative to pre-administration on days 1 and 7. 274 
Daurio et al. 1999 showed a more pronounced effect using an oral paste formulation of 275 
omeprazole at 4 mg/kg which inhibited both basal and pentagastrin-stimulated gastric acid 276 
secretion by 99% at 5-8 h after treatment and by 83% (basal) and 90% (pentagastrin-stimulated) 277 
at 21-24 hours. Sykes et al. 2017 have shown that dose and diet affect the response to 278 
omeprazole in the horse in an inconsistent manner. Clearly, there are several factors that 279 
influence the duration of effect of omeprazole which is not surprising given the fact it is a 280 
quasi-irreversible inhibitor of H+, K+-ATPase. A DT of 48 hours for oral omeprazole allows 281 
for both the herein suggested plasma and urine SLs as well as the duration of action observed 282 
in clinical equine studies.  283 
DTs are used by the treating veterinarian to recommend a withdrawal time (WT) for the drug 284 
before racing. WTs are longer than DTs as they include variability such as age, health and the 285 
particular drug product administered (Toutain, 2010). To extrapolate a WT experimentally, it 286 
is recommended to use an uncertainty factor determined from a Monte Carlo simulation which 287 
ensures that the 90th percentile of the population will not have a positive result. This simulation 288 
combines sources of variability simultaneously to generate an example population of DTs 289 
without completing a large population survey.  The proposed DT of 48 hours should therefore 290 
be converted using an uncertainty factor of 1.4 as outlined by Toutain 2010, to give a WT of 291 
72 hours. 292 
Orally administered omeprazole is an effective treatment for ESGD which can be debilitating, 293 
particularly in horses on which additional demands of competition are placed. In a study by 294 
Johnson et al. 2001, 403 horses treated for ESGD with omeprazole for 28 days at 4 mg/kg 295 
bodyweight per day showed 94% improvement, with 63% completely healed. This was 296 
reflected in a recent trial with 60 horses treated for ESGD, in which 88% showed improvement 297 
and 75% completely healed but in which the traditional 4 mg/kg per day dose was not the most 298 
effective; horses treated with 1 or 2 mg/kg per day showed 100% improvement and 89% healed, 299 
and 100% improvement and 94% healed respectively (Sykes, 2015b). The reported response 300 
rates for EGGD for oral omeprazole monotherapy are lower, with overall results at different 301 
doses (1, 2 and 4 mg/kg) showing 34% improvement and 14% complete healing (Sykes, 302 
2015b). It is therefore desirable that as far as possible within the principle of racing without the 303 
benefit of drugs, horses that need to be treated with omeprazole are treated in the confidence 304 
that they will neither risk a post-race adverse analytical finding (‘positive’) nor have their 305 
health compromised.  The new data reported herein for orally administered, in conjunction with 306 
other published studies, suggest that a plasma SL of 500 pg/mL should be used in addition to 307 
the existing urine ISL of the same concentration. A detection time of 48 hours is recommended 308 
which should assist those balancing what is best for an individual horse with what is needed to 309 
protect the integrity of the sport in which they are involved. 310 
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 399 
Table 1 Summary of plasma pharmacokinetic parameters for omeprazole following 400 
administration of 4 mg/kg once a day for five doses of UlcerGold® to six exercised 401 
Thoroughbred horses. 402 
 Horse 1 Horse 2 Horse 3 Horse 4 Horse 5 Horse 6 
Cmax (ng/mL) 2432 1242 435.8 1596 1329 1012 
tmax (h) 3.1 4.0 4.0 0.5 0.5 1.0 
t1/2 (h) 11 9.1 16 18 18 6.1 
AUC0-tau 
(ng.hr/mL) 
3625 4371 1476 2946 3139 1751 
Cavg (ng/mL) 151 182 62 123 131 73 
 403 
  404 
Table 2   Safety Factors relative to an EPC of 120 ng/mL and corresponding Detection Times  405 
Safety Factor Irrelevant Plasma 
Concentration (ng/mL) 
Detection Time (hrs) 
10 12 15 
50 2.4 23 
100 1.2 23 
500 0.24 47 
1000 0.12 71 
 406 
  407 
Table 3 Summary of urine pharmacokinetic parameters for omeprazole following 408 
administration of 4 mg/kg once a day for five doses UlcerGold® to six exercised 409 
Thoroughbred horses 410 
 Horse 1 Horse 2 Horse 3 Horse 4 Horse 5 Horse 6 
Cmax (ng/mL) 216.8 85.6 54.8 504.2 312.2 87.1 
Tmax (h) 5.3 11.1 3.5 1.8 1.9 2.1 
Detection time 
(h)* 
9.6 12.8 12.8 24.7 8.3 10.5 
Overall Time 
detected (h) ** 
28.2 26.6 29.9 47.3 25.7 70.9 
*Above the SL of 500 pg/mL 411 
**Above LOD of the method 412 
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